AlloVir Stock Price, News & Analysis (NASDAQ:ALVR) $2.26 +0.22 (+10.78%) (As of 12/6/2023 ET) Add Compare Share Share Today's Range$2.06▼$2.3250-Day Range$1.34▼$2.2652-Week Range$1.31▼$7.36Volume864,912 shsAverage Volume590,318 shsMarket Capitalization$257.78 millionP/E RatioN/ADividend YieldN/APrice Target$18.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media AlloVir MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside729.6% Upside$18.75 Price TargetShort InterestBearish10.17% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$37,132 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.71) to ($1.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 starsMedical Sector639th out of 957 stocksBiological Products, Except Diagnostic Industry93rd out of 147 stocks 3.5 Analyst's Opinion Consensus RatingAlloVir has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.75, AlloVir has a forecasted upside of 729.6% from its current price of $2.26.Amount of Analyst CoverageAlloVir has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.17% of the outstanding shares of AlloVir have been sold short.Short Interest Ratio / Days to CoverAlloVir has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.Change versus previous monthShort interest in AlloVir has recently increased by 2.38%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAlloVir does not currently pay a dividend.Dividend GrowthAlloVir does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALVR. Previous Next 0.6 News and Social Media Coverage Search Interest5 people have searched for ALVR on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added AlloVir to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AlloVir insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $37,132.00 in company stock.Percentage Held by Insiders39.97% of the stock of AlloVir is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.41% of the stock of AlloVir is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for AlloVir are expected to grow in the coming year, from ($1.71) to ($1.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AlloVir is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AlloVir is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlloVir has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AlloVir Stock (NASDAQ:ALVR)Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.Read More ALVR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALVR Stock News HeadlinesNovember 16, 2023 | finance.yahoo.comAlloVir to Present at the Piper Sandler 35th Annual Healthcare ConferenceNovember 3, 2023 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on AlloVir (ALVR)December 7, 2023 | Edge On The Street (Ad)Henry Ford Would NEVER Have Seen This ComingIn 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.November 2, 2023 | morningstar.comAlloVir Inc Ordinary Shares ALVRNovember 2, 2023 | finance.yahoo.comAlloVir Inc (ALVR) Reports Q3 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comAlloVir Reports Third Quarter 2023 Financial ResultsSeptember 23, 2023 | fool.comAlloVir (NASDAQ: ALVR)September 21, 2023 | fool.comWhy AlloVir Stock Dropped TodayDecember 7, 2023 | Edge On The Street (Ad)Henry Ford Would NEVER Have Seen This ComingIn 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.September 15, 2023 | finance.yahoo.comWe're Keeping An Eye On AlloVir's (NASDAQ:ALVR) Cash Burn RateAugust 28, 2023 | finance.yahoo.comAlloVir to Present at Upcoming Investor ConferencesAugust 18, 2023 | msn.comAlloVir spikes as Bank of America starts at Buy on lead assetAugust 18, 2023 | markets.businessinsider.comAlloVir's RSV Therapy Is Underappreciated Gem, BofA Comments On Future PotentialAugust 18, 2023 | msn.comB of A Securities Initiates Coverage of AlloVir (ALVR) with Buy RecommendationAugust 18, 2023 | markets.businessinsider.comBank of America Securities Initiates a Buy Rating on AlloVir (ALVR)August 8, 2023 | msn.comMorgan Stanley Reiterates AlloVir (ALVR) Overweight RecommendationAugust 6, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: AlloVir (ALVR), Cytokinetics (CYTK) and Guardant Health (GH)August 3, 2023 | finance.yahoo.comAlloVir Reports Second Quarter 2023 Financial ResultsJuly 10, 2023 | msn.comAlloVir: 'Takes One To Know One'June 29, 2023 | msn.comBlackBerry, Micron And Other Big Stocks Moving Higher In Thursday's Pre-Market SessionJune 27, 2023 | finance.yahoo.comAlloVir, Inc. (ALVR) Upgraded to Buy: Here's WhyJune 23, 2023 | finance.yahoo.comWhy Shares of AlloVir Plummeted This WeekJune 22, 2023 | nasdaq.comAlloVir Prices Public OfferingJune 22, 2023 | benzinga.comWhy AlloVir Stock Is Diving ThursdayJune 22, 2023 | investorplace.comWhy Is AlloVir (ALVR) Stock Down 23% Today?June 22, 2023 | seekingalpha.comAlloVir shares slide on pricing $75M of stock offeringJune 22, 2023 | markets.businessinsider.comPre-market Movers: PIXY, ROOT, CDMO, ALVR, KWE…See More Headlines Receive ALVR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AlloVir and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALVR CUSIPN/A CIK1754068 Webwww.allovir.com Phone617-433-2605FaxN/AEmployees114Year FoundedN/APrice Target and Rating Average Stock Price Target$18.75 High Stock Price Target$20.00 Low Stock Price Target$17.00 Potential Upside/Downside+729.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-168,710,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-80.17% Return on Assets-64.20% Debt Debt-to-Equity RatioN/A Current Ratio6.65 Quick Ratio6.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.41 per share Price / Book0.94Miscellaneous Outstanding Shares114,064,000Free Float68,473,000Market Cap$257.78 million OptionableNot Optionable Beta1.03 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. David L. Hallal (Age 57)Executive Chairman of the Board Comp: $254.38kDr. Diana M. Brainard M.D. (Age 52)CEO & Director Comp: $978.99kMr. Vikas Sinha C.A. (Age 60)CPA, M.B.A., President, CFO & Director Comp: $536.21kMr. Edward Miller J.D. (Age 58)General Counsel & Secretary Comp: $618.39kMr. Brett R. Hagen (Age 50)Chief Accounting Officer Mr. Dana M. Alexander (Age 47)Senior Vice President of Technical Operations Dr. Ann M. Leen Ph.D. (Age 46)Chief Scientific Officer Ms. Sonia ChoiSenior Vice President of Corporate Affairs & Investor RelationsMr. Ugo Capolino PerlingieriHead & GM of Europe and Middle East OperationsMs. Cintia Piccina Pharm.D. (Age 50)Chief Commercial Officer More ExecutivesKey CompetitorsFate TherapeuticsNASDAQ:FATECompass TherapeuticsNASDAQ:CMPXFennec PharmaceuticalsNASDAQ:FENCInnate PharmaNASDAQ:IPHASOPHiA GENETICSNASDAQ:SOPHView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 200,178 shares on 12/1/2023Ownership: 0.524%Graham Capital Management L.P.Bought 11,962 shares on 11/22/2023Ownership: 0.010%Diana BrainardSold 4,382 sharesTotal: $7,405.58 ($1.69/share)Vikas SinhaSold 2,490 sharesTotal: $4,058.70 ($1.63/share)Diana BrainardSold 2,689 sharesTotal: $4,383.07 ($1.63/share)View All Insider TransactionsView All Institutional Transactions ALVR Stock Analysis - Frequently Asked Questions Should I buy or sell AlloVir stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AlloVir in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALVR shares. View ALVR analyst ratings or view top-rated stocks. What is AlloVir's stock price target for 2024? 3 brokers have issued 12 month price targets for AlloVir's shares. Their ALVR share price targets range from $17.00 to $20.00. On average, they anticipate the company's share price to reach $18.75 in the next twelve months. This suggests a possible upside of 729.6% from the stock's current price. View analysts price targets for ALVR or view top-rated stocks among Wall Street analysts. How have ALVR shares performed in 2023? AlloVir's stock was trading at $5.13 at the beginning of the year. Since then, ALVR shares have decreased by 55.9% and is now trading at $2.26. View the best growth stocks for 2023 here. When is AlloVir's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024. View our ALVR earnings forecast. How were AlloVir's earnings last quarter? AlloVir, Inc. (NASDAQ:ALVR) posted its earnings results on Thursday, November, 2nd. The company reported ($0.39) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.03. What other stocks do shareholders of AlloVir own? Based on aggregate information from My MarketBeat watchlists, some companies that other AlloVir investors own include Advanced Micro Devices (AMD), Cloudera (CLDR), Infinera (INFN), Sonos (SONO), Trevena (TRVN), Abbott Laboratories (ABT), Boeing (BA), Delta Air Lines (DAL), Datadog (DDOG) and FuelCell Energy (FCEL). When did AlloVir IPO? (ALVR) raised $252 million in an IPO on Thursday, July 30th 2020. The company issued 14,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. Who are AlloVir's major shareholders? AlloVir's stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (8.49%), Massachusetts Financial Services Co. MA (0.73%), Wellington Management Group LLP (0.52%), Northern Trust Corp (0.42%), Charles Schwab Investment Management Inc. (0.36%) and Bank of New York Mellon Corp (0.15%). Insiders that own company stock include Agustin Melian, Ann M Leen, Beek Jeroen B Van, Beek Jeroen B Van, Brett R Hagen, David Hallal, Diana Brainard, Edward Miller, Ercem Atillasoy, Gilead Sciences, Inc, Jeffrey S Bornstein, John Robert Wilson, Juan Vera, Morana Jovan-Embiricos and Vikas Sinha. View institutional ownership trends. How do I buy shares of AlloVir? Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ALVR) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.